The term Interstitial Lung Disease (ILD) characterizes more than 100 distinct disorders with vastly different treatment approaches and responses to therapy. Such a wide-ranging disease portfolio requires an equally comprehensive approach to diagnosis and treatment, and for that the University of Michigan utilizes a multidisciplinary team approach.
Anchored by weekly conferences, the U-M Interstitial Lung Disease Program brings together experts from pulmonology, radiology and pathology to review case material and assign an accurate diagnosis (or determine if additional tests are required to achieve a diagnosis). Once a diagnosis is achieved, the U-M ILD program utilizes collaborative expertise from additional specialties to aid in treatment. These specialists may include rheumatology, cardiology, gastroenterology, pulmonary hypertension, sleep medicine, lung transplantation, pulmonary rehabilitation, nursing and other support services. This collaborative team approach to treatment allows for consideration of the best standard and/or research approaches to each case. Communication between the U-M ILD program and the patient’s referring physician helps to coordinate ongoing care locally when possible.
Idiopathic pulmonary fibrosis is a specific type of ILD. Two drugs (pirfenidone and nintedanib) were approved for the treatment of IPF (but not other ILDs) by the FDA in October, 2014. The approval of these drugs specifically to treat IPF further highlights the importance of an accurate diagnosis.
The University of Michigan Interstitial Lung Disease Program is also at the forefront of researching, developing and testing novel therapeutic approaches, from basic science studies through translational research. U-M is among the top centers in the U-S in participating in ILD clinical trials, including many trials that originate here.
Ours is one of the first programs in the U.S. to demonstrate how well this approach works for ILD. We have published extensively on our methods, setting the nationwide standard of multidisciplinary care and innovative research in ILD.
For an interstitial lung disease referral, call us at 888-287-1084.
The U-M ILD Program treats the full range of related conditions, including but not limited to:
- Idiopathic Pulmonary Fibrosis (IPF)
- Non-specific Interstitial Pneumonia (NSIP)
- Scarring disease of the lung associated with autoimmune diseases such as lupus, scleroderma, myositis, rheumatoid arthritis and mixed connective tissue disease
- Respiratory bronchiolitis
- Pulmonary alveolar proteinosis
- Granulomatosis with polyangiitis
- Hypersensitivity pneumonitis
- Rheumatoid lung
- Evaluation for lung transplant